Sector News

BioAmber announces changes to Board of Directors

February 23, 2016
Life sciences

/PRNewswire/ – BioAmber Inc., a leader in renewable materials, today announced that George F.J. Gosbee is joining its board of directors, effective today. Mr. Gosbee will replace Henry “Pete” Linsert, Jr. who resigned his board seat for personal reasons, effective today.

George Gosbee brings extensive capital markets experience and deep knowledge of the oil and gas industry. His profile is complementary to existing board members and he will provide insight and advice on navigating capital markets, positioning the company vs. fossil fuels, approaching new investors and raising the Company’s visibility. Mr. Gosbee has been elected a Class II director, to hold office until the 2018 annual meeting of stockholders. Mr. Gosbee will serve on the Nominating and Corporate Governance Committee and the Compensation Committee.

“On behalf of the entire board and management team, I would like to thank Pete for his valuable insight and contributions over the past 20 months,” said Ray Land, Chairman of the board. “Pete’s experience and wisdom will be missed, but we are thrilled to have someone of George’s caliber and financial background joining the board.”

About George F.J. Gosbee

Mr. Gosbee’s career spans over 20 years in corporate finance, investment banking, global capital markets and advisory. Prior to founding AltaCorp Capital in 2010, Mr. Gosbee was Chairman, President and CEO of Tristone Capital Global Inc., a global energy investment firm which he founded. Tristone became the largest global independent energy advisory firm and was acquired by an international bank in 2009. His current firm, AltaCorp Capital, is an advisory firm that is partnered with Alberta Treasury Branch (ATB Financial), a wholly owned subsidiary of the Government of Alberta.

Mr. Gosbee is a former Governor of the National Hockey League (NHL). He led a group to purchase the Arizona Coyotes and restructure the Club. Currently he is an Alternate Governor on the NHL Board of Governors and Co-owner of the Arizona Coyotes.

Mr. Gosbee was the Vice Chairman of Alberta Investment Management Co (AIMCo) and was called on to assist in the creation of the crown corporation. He spent 8 years as the Vice Chair of AIMCo, which is a $90 billion institutional investment fund, and currently is a Director. Mr. Gosbee is a former Director of the TMX Group and a former Board Member of Chrysler Group LLC in Detroit, where he served on behalf of both the Canadian Federal and Provincial (Ontario) governments to oversee their collective investment in the company and assist in the restructuring.

Source: BioAmber

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”